Captor Therapeutics S.A. Cash Flow Conversion Efficiency
Captor Therapeutics S.A. cash flow conversion efficiency. Based on the latest financial reports, Captor Therapeutics S.A. (CTX) has a cash flow conversion efficiency ratio of -0.346x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-11.51 Million ≈ $-3.17 Million USD) by net assets (zł33.27 Million ≈ $9.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Captor Therapeutics S.A. (2017–2024)
Cash flow conversion efficiency of Captor Therapeutics S.A. from 2017 to 2024. This chart illustrates how Captor Therapeutics S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View CTX stock price and chart for real-time trading data and today's change.
Captor Therapeutics S.A. Cash Flow Conversion Ratio Explained
Captor Therapeutics S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Captor Therapeutics S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Captor Therapeutics S.A. ranked by their cash flow conversion efficiency. Also see CTX market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Canna Global Acquisition Corp
NYSE:CNGL
|
-0.413x |
|
Clipan Finance Indonesia Tbk
JK:CFIN
|
0.093x |
|
SUI Group Holdings Limited
NASDAQ:SUIG
|
-0.023x |
|
Brompton Lifeco Split Corp
TO:LCS
|
-0.005x |
|
Talga Group Ltd
AU:TLG
|
-0.155x |
|
C&G Hi Tech Co.Ltd
KQ:264660
|
0.021x |
|
Alkim Kagit Sanayi ve Ticaret AS
IS:ALKA
|
1.752x |
|
RMK Energy PT Tbk
JK:RMKE
|
-0.081x |
Annual Cash Flow Conversion Efficiency for Captor Therapeutics S.A. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Captor Therapeutics S.A. from 2017 to 2024. Review Captor Therapeutics S.A. (CTX) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł64.47 Million ≈ $17.74 Million |
zł-31.88 Million ≈ $-8.77 Million |
-0.494x | +34.44% |
| 2023-12-31 | zł69.22 Million ≈ $19.05 Million |
zł-52.20 Million ≈ $-14.37 Million |
-0.754x | -216.56% |
| 2022-12-31 | zł96.32 Million ≈ $26.51 Million |
zł-22.95 Million ≈ $-6.32 Million |
-0.238x | -3.92% |
| 2021-12-31 | zł124.20 Million ≈ $34.18 Million |
zł-28.47 Million ≈ $-7.84 Million |
-0.229x | -138.68% |
| 2020-12-31 | zł-1.00 Million ≈ $-276.32K |
zł-595.00K ≈ $-163.75K |
0.593x | -42.31% |
| 2019-12-31 | zł4.28 Million ≈ $1.18 Million |
zł4.39 Million ≈ $1.21 Million |
1.027x | +265.41% |
| 2018-12-31 | zł3.43 Million ≈ $944.26K |
zł-2.13 Million ≈ $-586.48K |
-0.621x | -104.27% |
| 2017-12-31 | zł144.00K ≈ $39.63K |
zł2.10 Million ≈ $577.12K |
14.563x | -- |
About Captor Therapeutics S.A.
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. … Read more